CLAIM #23017 · EMR (EMR) · 2026Q2 earnings call · May 5, 2026 · due Sep 30, 2026
“We now expect sales growth of 4.5% with underlying growth of 3%.”
Lal Karsanbhai · CEO
PENDING
graded after results covering Sep 30, 2026 are reported
How to check this claim
Look at: Net sales growth (total reported) and underlying sales growth, fiscal year
It came true if: Total sales growth between 4.0% and 5.0%, and underlying sales growth between 2.5% and 3.5%
Where: Company income statement and management commentary (10-K / Q4 earnings release and call)
Verify independently
SEC filings for EMR ↗ · Claim quote is verbatim from the 2026Q2 earnings call.